Morris Charles A, Cabral Danielle, Cheng Hailu, Katz Jeffrey N, Finkelstein Joel S, Avorn Jerry, Solomon Daniel H
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA.
J Gen Intern Med. 2004 Jul;19(7):783-90. doi: 10.1111/j.1525-1497.2004.30240.x.
To identify potential obstacles to bone mineral density (BMD) testing, we performed a structured review of current osteoporosis screening guidelines, studies of BMD testing patterns, and interventions to increase BMD testing.
We searched medline and HealthSTAR from 1992 through 2002 using appropriate search terms. Two authors examined all retrieved articles, and relevant studies were reviewed with a structured data abstraction form.
A total of 235 articles were identified, and 51 met criteria for review: 24 practice guidelines, 22 studies of screening patterns, and 5 interventions designed to increase BMD rates. Of the practice guidelines, almost one half (47%) lacked a formal description of how they were developed, and recommendations for populations to screen varied widely. Screening frequencies among at-risk patients were low, ranging from 1% to 47%. Only eight studies assessed factors associated with BMD testing. Female patient gender, glucocorticoid dose, and rheumatologist care were positively associated with BMD testing; female physicians, rheumatologists, and physicians caring for more postmenopausal patients were more likely to test patients. Five articles described interventions to increase BMD testing rates, but only two tested for statistical significance and no firm conclusions can be drawn.
This systematic review identified several possible contributors to suboptimal BMD testing rates. Osteoporosis screening guidelines lack uniformity in their development and content. While some patient and physician characteristics were found to be associated with BMD testing, few articles carefully assessed correlates of testing. Almost no interventions to improve BMD testing to screen for osteoporosis have been rigorously evaluated.
为了确定骨密度(BMD)检测的潜在障碍,我们对当前骨质疏松症筛查指南、骨密度检测模式研究以及提高骨密度检测的干预措施进行了结构化综述。
我们使用适当的检索词在1992年至2002年期间检索了医学文献数据库(Medline)和健康之星数据库(HealthSTAR)。两位作者检查了所有检索到的文章,并使用结构化数据提取表对相关研究进行了综述。
共识别出235篇文章,其中51篇符合综述标准:24篇实践指南、22篇筛查模式研究以及5项旨在提高骨密度检测率的干预措施。在实践指南中,近一半(47%)缺乏对其制定方式的正式描述,针对筛查人群的建议差异很大。高危患者的筛查频率较低,范围从1%到47%。只有八项研究评估了与骨密度检测相关的因素。女性患者性别、糖皮质激素剂量和风湿病医生的诊治与骨密度检测呈正相关;女医生、风湿病医生以及诊治更多绝经后患者的医生更有可能为患者进行检测。五篇文章描述了提高骨密度检测率的干预措施,但只有两篇进行了统计学意义检验,无法得出确切结论。
这项系统综述确定了几个可能导致骨密度检测率不理想的因素。骨质疏松症筛查指南在制定和内容上缺乏一致性。虽然发现一些患者和医生特征与骨密度检测有关,但很少有文章仔细评估检测的相关因素。几乎没有针对改善骨密度检测以筛查骨质疏松症的干预措施得到严格评估。